宫腔粘连分离术后不同处理方式对预防再粘连的疗效

注册号:

Registration number:

ChiCTR1800019391 

最近更新日期:

Date of Last Refreshed on:

2018-11-08 23:06:50 

注册时间:

Date of Registration:

2018-11-08 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

宫腔粘连分离术后不同处理方式对预防再粘连的疗效

Public title:

Different treatments for adhesion prevention after hysteroscopic adhesiolysis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

宫腔粘连分离术后不同处理方式对预防再粘连的疗效

Scientific title:

Different treatments for adhesion prevention after hysteroscopic adhesiolysis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

欧妙娴 

研究负责人:

刘明星 

Applicant:

Miaoxian Ou 

Study leader:

Mingxing Liu 

申请注册联系人电话:

Applicant telephone:

+86 13798164848

研究负责人电话:

Study leader's
telephone:

+86 18926230320

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

drmiaomx@163.com

研究负责人电子邮件:

Study leader's E-mail:

mxliu_gzh@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广州市荔湾区多宝路63号广州医科大学附属第三医院妇产科门诊

研究负责人通讯地址:

广州市荔湾区多宝路63号广州医科大学附属第三医院妇产科门诊

Applicant address:

63 Duobao Road, Liwan District, Guangzhou, Guangdong, China

Study leader's address:

63 Duobao Road, Liwan District, Guangzhou, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

510150

研究负责人邮政编码:

Study leader's postcode:

510150

申请人所在单位:

广州医科大学附属第三医院

Applicant's institution:

The Third Affiliated Hospital of Guangzhou Medical University

研究负责人所在单位:

广州医科大学附属第三医院

Affiliation of the Leader:

The Third Affiliated Hospital of Guangzhou Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

医伦快审【2018】第063号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广州医科大学附属第三医院伦理委员会

Name of the ethic committee:

the Ethics Committee of the Third Affiliated Hospital of Guangzhou Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2018-10-31 00:00:00

伦理委员会联系人:

廖绮霞

Contact Name of the ethic committee:

QixiaLiao

伦理委员会联系地址:

广州市荔湾区多宝路63号广州医科大学附属第三医院伦理科

Contact Address of the ethic committee:

The Ethics Department, the Third Affiliated Hospital of Guangzhou Medical University, 63 Duobao Road, Liwan District, Guangzhou, Guangdong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广州医科大学附属第三医院

Primary sponsor:

The Third Affiliated Hospital of Guangzhou Medical University

研究实施负责(组长)单位地址:

广州市荔湾区多宝路63号广州医科大学附属第三医院

Primary sponsor's address:

63 Duobao Road, Liwan District, Guangzhou, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

广州市

Country:

China

Province:

Guangdong

City:

Guangzhou City

单位(医院):

广州医科大学附属第三医院

具体地址:

广州市荔湾区多宝路63号广州医科大学附属第三医院

Institution
hospital:

The Third Affiliated Hospital of Guangzhou Medical University

Address:

63 Duobao Road, Liwan District, Guangzhou, Guangdong, China

经费或物资来源:

自筹

Source(s) of funding:

self-raised

研究疾病:

宫腔粘连  

Target disease:

intrauterine adhesion

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本课题拟探讨中度宫腔粘连分离术后,一周后宫腔内注射新型防粘连剂及行球囊扩张对预防宫腔再粘连的有效性  

Objectives of Study:

To discuss the effectiveness of injection of new anti-adhesion agent and balloon dilation for the prevention of intrauterine re-adhesion after hysteroscopic adhesiolysis.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

①年龄<20,>40岁;②BMI≤20kg/m2 ,≥25kg/m2;③AFS评分为轻度或重度者即<5分及>8分;④粘连由子宫内膜结核所致;⑤有使用雌激素、IUD、庆大霉素、地塞米松、糜蛋白酶等禁忌症;⑥3个月内使用其他雌、孕激素;⑦有全身疾病,如血栓性疾病,肝肾损害等不能耐受手术者。

Exclusion criteria:

1. With contraindications such as estrogen, IUD, gentamicin, dexamethasone, chymotrypsin; vaginitis, infection or systemic disease;
2. adhesions are caused by endometrial tuberculosis;
3. usage other estrogen and progesterone in past 3 months;
4. systemic diseases such as thrombotic disease, liver and kidney disease.

研究实施时间:

Study execute time:

From 2018-10-15 00:00:00 To 2019-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2018-11-15 00:00:00 To 2019-04-30 00:00:00

干预措施:

Interventions:

组别:

1

样本量:

60

Group:

Group 1

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

2

样本量:

60

Group:

Group 2

Sample size:

干预措施:

宫腔注射防粘连剂

干预措施代码:

Intervention:

inject anti-adhesion agent in the uterine

Intervention code:

组别:

3

样本量:

60

Group:

Group 3

Sample size:

干预措施:

Foley球囊扩张

干预措施代码:

Intervention:

Foley balloon dilatation

Intervention code:

组别:

4

样本量:

60

Group:

Group 4

Sample size:

干预措施:

Foley球囊扩张+宫腔注射防粘连剂

干预措施代码:

Intervention:

Foley balloon dilatation+inject anti-adhesion agent in the uterine

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

广州市 

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州医科大学附属第三医院 

单位级别:

三级甲等 

Institution
hospital:

The Third Affiliated Hospital of Guangzhou Medical University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

1988年美国生育学会宫腔粘连评分标准

指标类型:

主要指标

Outcome:

The American Fertility Society classifications of intrauterine adhesions

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

月经量

指标类型:

次要指标

Outcome:

menstrual blood volume

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

妊娠率

指标类型:

次要指标

Outcome:

rate of pregnance

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

活产率

指标类型:

次要指标

Outcome:

live birth rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

宫腔粘连再发率

指标类型:

主要指标

Outcome:

reformation rates

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 40 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

电脑随机数字法

Randomization Procedure (please state who generates the random number sequence and by what method):

Computer random number method

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

未说明

Blinding:

Not stated

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后公开,ResMan

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

afterthetrial complete,ResMan

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Excel,ResMan

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Excel,ResMan

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2018-11-08 23:06:50